0.4971
Talphera Inc (TLPH) 最新ニュース
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com India
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India
Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks
FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan
TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com
Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million - PR Newswire
Earnings Outlook For Talphera - Benzinga
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 - Longview News-Journal
Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - Stock Titan
Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com
Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter
Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register
RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World
Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN
Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada
FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria
FDA to review Talphera's request to amend NEPHRO study - Investing.com
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online
TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK
TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com
Talphera faces Nasdaq delisting over share price rule - Investing.com
Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK
Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com
大文字化:
|
ボリューム (24 時間):